ACADIA Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACAD) $20.91 -0.88 (-4.04%) (As of 01:57 PM ET) Add Compare Share Share Today's Range$20.87▼$21.7350-Day Range$20.78▼$24.0752-Week Range$14.48▼$33.99Volume686,448 shsAverage Volume1.54 million shsMarket Capitalization$3.43 billionP/E RatioN/ADividend YieldN/APrice Target$35.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media ACADIA Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside65.9% Upside$35.67 Price TargetShort InterestBearish4.74% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.04Based on 12 Articles This WeekInsider TradingSelling Shares$1.82 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.33) to $0.94 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsMedical Sector188th out of 960 stocksPharmaceutical Preparations Industry47th out of 378 stocks 4.4 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.67, ACADIA Pharmaceuticals has a forecasted upside of 65.9% from its current price of $21.50.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.74% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently increased by 3.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 1.1 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for ACADIA Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -79% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,816,427.00 in company stock.Percentage Held by Insiders27.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.29% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow in the coming year, from ($0.33) to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -23.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -23.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 8.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.Read More ACAD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACAD Stock News HeadlinesDecember 8, 2023 | americanbankingnews.comQ3 2025 EPS Estimates for ACADIA Pharmaceuticals Inc. Decreased by Zacks Research (NASDAQ:ACAD)December 8, 2023 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Rating Increased to Buy at StockNews.comDecember 8, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 6, 2023 | fool.com.auUp 118%: Is this 'high quality' stock the best-kept secret on the ASX 200?December 3, 2023 | americanbankingnews.comStockNews.com Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) to HoldDecember 1, 2023 | msn.comAcadia starts Phase III study of PWS therapyDecember 1, 2023 | msn.comAcadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWSNovember 30, 2023 | msn.comAcadia starts Phase 3 study for Prader-Willi hunger treatmentDecember 8, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 29, 2023 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Recommendation of "Moderate Buy" by BrokeragesNovember 28, 2023 | msn.comAcadia Pharmaceuticals begins trial of Alzheimer’s psychosis drugNovember 28, 2023 | benzinga.comACADIA Pharmaceuticals Stock (NASDAQ:ACAD) Dividends: History, Yield and DatesNovember 28, 2023 | finance.yahoo.comAcadia (ACAD) Begins Alzheimer's Disease Psychosis StudyNovember 22, 2023 | morningstar.comACADIA Pharmaceuticals Inc ACADNovember 22, 2023 | finance.yahoo.comInsider Sell Alert: EVP Brendan Teehan Sells Shares of ACADIA Pharmaceuticals IncNovember 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Morphosys Ag (MOR) and Enanta Pharmaceuticals (ENTA)November 21, 2023 | marketwatch.comAcadia Pharmaceuticals' Research and Development Head to ExitNovember 21, 2023 | finance.yahoo.comAcadia Pharmaceuticals Announces Change in Research and Development LeadershipNovember 20, 2023 | finance.yahoo.comWall Street Analysts Predict a 37.65% Upside in Acadia (ACAD): Here's What You Should KnowNovember 17, 2023 | finance.yahoo.comAre Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year?November 17, 2023 | finance.yahoo.comAre Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year?November 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), ACADIA Pharmaceuticals (ACAD) and Personalis (PSNL)November 7, 2023 | markets.businessinsider.comHold Rating on ACADIA Pharmaceuticals: Balancing Growth Potential, Discontinuation Risks, and IP Litigation ConcernsNovember 7, 2023 | msn.comMizuho Upgrades Acadia Pharmaceuticals (ACAD)November 4, 2023 | finance.yahoo.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2023 Earnings Call TranscriptNovember 3, 2023 | markets.businessinsider.comACADIA Pharmaceuticals Earns Buy Rating: Strong Q3 Performance, Promising Pipeline, and Market Dominance HighlightedNovember 3, 2023 | markets.businessinsider.comPromising ADVANCE-2 Trial Results Bolster ACADIA Pharmaceuticals’ Buy Rating: An Analysis by Andrew FeinSee More Headlines Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees580Year FoundedN/APrice Target and Rating Average Stock Price Target$35.67 High Stock Price Target$95.00 Low Stock Price Target$15.00 Potential Upside/Downside+63.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-215,980,000.00 Net Margins-23.55% Pretax Margin-20.83% Return on Equity-38.84% Return on Assets-23.64% Debt Debt-to-Equity RatioN/A Current Ratio2.38 Quick Ratio2.28 Sales & Book Value Annual Sales$631.89 million Price / Sales5.66 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book8.82Miscellaneous Outstanding Shares164,180,000Free Float119,031,000Market Cap$3.58 billion OptionableOptionable Beta0.59 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Stephen R. Davis J.D. (Age 62)President, CEO & Director Comp: $1.46MMr. Mark C. Schneyer (Age 49)Executive VP & CFO Comp: $701.03kMr. Brendan P. Teehan (Age 54)Executive VP, COO & Head of Commercial Comp: $724.31kMr. Austin D. Kim (Age 59)Executive VP, General Counsel & Secretary Comp: $722.15kMr. James K. Kihara (Age 42)VP, Chief Accounting Officer & Corporate Controller Mr. Albert S. KildaniSenior Vice President of Investor Relations & Corporate CommunicationsMs. Julie FisherSenior Vice President of Marketing & Commercial StrategyMs. Holly ValdiviezSenior VP & Head of SalesMr. Rob AcklesSenior VP & Chief People OfficerMr. Bob MischlerSenior Vice President of New Product Planning & StrategyMore ExecutivesKey CompetitorsEvotecNASDAQ:EVOUltragenyx PharmaceuticalNASDAQ:RAREInsmedNASDAQ:INSMMirati TherapeuticsNASDAQ:MRTXAmicus TherapeuticsNASDAQ:FOLDView All CompetitorsInsiders & InstitutionsCitigroup Inc.Bought 2,786 shares on 12/6/2023Ownership: 0.089%American Century Companies Inc.Bought 117,092 shares on 11/30/2023Ownership: 0.081%Deutsche Bank AGSold 1,329,124 shares on 11/24/2023Ownership: 0.041%Hohimer Wealth Management LLCSold 750 shares on 11/21/2023Ownership: 0.010%Walleye Capital LLCBought 8,700 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ACAD Stock Analysis - Frequently Asked Questions Should I buy or sell ACADIA Pharmaceuticals stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACAD shares. View ACAD analyst ratings or view top-rated stocks. What is ACADIA Pharmaceuticals' stock price target for 2024? 12 equities research analysts have issued 1 year target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price targets range from $15.00 to $95.00. On average, they anticipate the company's share price to reach $35.67 in the next year. This suggests a possible upside of 65.9% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. How have ACAD shares performed in 2023? ACADIA Pharmaceuticals' stock was trading at $15.92 on January 1st, 2023. Since then, ACAD shares have increased by 35.1% and is now trading at $21.50. View the best growth stocks for 2023 here. When is ACADIA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our ACAD earnings forecast. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.03. The biopharmaceutical company had revenue of $211.70 million for the quarter, compared to analysts' expectations of $194.40 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 38.84% and a negative net margin of 23.55%. What ETFs hold ACADIA Pharmaceuticals' stock? ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Invesco Biotechnology & Genome ETF (PBE), First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL). Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include RTW Investments LP (7.05%), FMR LLC (3.23%), Fred Alger Management LLC (1.89%), Morgan Stanley (1.13%), Emerald Advisers LLC (1.03%) and Jacobs Levy Equity Management Inc. (0.87%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ACAD) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.